thanks Beaza. I had a look at a couple of the ASX announcements by RAC for this info but I couldn’t find it. Pretty heavily pretreated population with failing on average 4 lines of therapy before joining the RAC study. Not a huge amount of detail on CHMs trial but I expect a similar patient profile given patients will typically fail or are ineligible for the standard of care therapy before joining the trial.
thanks Beaza. I had a look at a couple of the ASX announcements...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $69.79K | 17.44M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 26298938 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 9548289 | 12 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |